Journal
MOLECULAR AND CELLULAR ENDOCRINOLOGY
Volume 351, Issue 2, Pages 129-141Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.mce.2011.08.036
Keywords
Liver X receptors; Pharmacology; SLiMs; Human pathologies; Cholesterol; Nuclear receptors
Categories
Funding
- Association de Recherche sur les Tumeurs Prostatiques
- Ligue Allier contre le Cancer
- Association de Recherches contre le Cancer
- FRM
- Fondation BNP
- Region Auvergne
- Fond Europeen de DEveloppement Regional (FEDER)
- MNERT
Ask authors/readers for more resources
Liver X receptors (LXR) are members of the nuclear receptor family. As activated transcription factors, their putative association with human diseases makes them promising pharmacological targets because of the large potential to develop ligands. LXR are mainly considered as intracellular cholesterol sensors whose activation leads to decreased plasma cholesterol. They also modulate numerous physiological functions: fatty acid synthesis and metabolism, glucose homeostasis, steroidogenesis, immunity, and neurological homeostasis. LXR-deficiency in mouse results in several phenotypes mimicking pathological conditions in humans. This review will be focused on the various natural and synthetic LXR agonists and antagonists. Putative clinical targets including atherosclerosis, diabetes. Alzheimer's disease, skin disorders, and cancer will be covered. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available